The U.S. Food and Drug Administration announced recently that it will conduct a safety review of birth control pills that contain the progestin hormone, drospirenone. The review was prompted by the findings of two published studies which assert that women taking birth control pills containing drospirenone may have an increased risk of developing blood clots.
Brand names of drospirenone-containing products include: Yaz (its generics, Gianvi and Loryna), Yasmin (its generics, Ocella, Syeda and Zarah), Beyaz and Safryral. While blood clots are a potential side effect of all birth control pills, the data from the two new reports caused the FDA to state, “This risk is reported to be up to two to three times greater than the risk of thromboembolism associated with using levonorgestrel-containing pills.”
The FDA’s safety review will involve more than 800,000 U.S. women and results are expected later this summer.